Activity

Activity ID

10687

Expires

October 1, 2026

Format Type

Journal-based

CME Credit

1

Fee

$30

CME Provider: AMA Journal of Ethics

Description of CME Course

Alzheimer’s disease (AD) is an incurable, progressive deterioration that ends, eventually, in death. For many years, AD’s hallmark etiological feature was beta-amyloid plaque accumulation in the brain, but, to date, costly drugs designed to reduce beta-amyloid levels offer only marginal clinical benefit and pose significant risk of harm. Thus, there is strong interest in finding alternative AD-modifying interventions, and, despite controversy, aducanumaban antibodyrecently received approval by the US Food and Drug Administration. This article considers how ethical issues in the care of patients with AD could influence, for better or worse, clinicians’ judgment about whether and when to recommend aducanumab.

Disclaimers

1. This activity is accredited by the American Medical Association.
2. This activity is free to AMA members.

Register for this Activity

ABMS Member Board Approvals by Type
More Information
Commercial Support?
No

NOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.

Educational Objectives

1. Explain a new or unfamiliar viewpoint on a topic of ethical or professional conduct
2. Evaluate the usefulness of this information for health care practice, teaching, or conduct
3. Decide whether and when to apply the new information to health care practice, teaching, or conduct

Keywords

Ethics, Dementia and Cognitive Impairment, Neurology

Competencies

Medical Knowledge, Professionalism

CME Credit Type

AMA PRA Category 1 Credit

DOI

10.1001/amajethics.2023.782

View All Activities by this CME Provider

The information provided on this page is subject to change. Please refer to the CME Provider’s website to confirm the most current information.